Proof of concept confirmed in relevant in vitro and in vivo models
OSE-127 (Effi-7) has shown efficacy in preclinical models of T-cell-mediated inflammation, with an immediate and long-lasting effect, conferring the product a novel mechanism of action.
The strategy of blocking IL-7R, which is different from conventional or new anti-inflammatory drugs used in the clinic, demonstrated its efficacy in several preclinical models, restoring the impaired immune balance in inflammatory bowel diseases (references), type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Read more >
It also enabled the promotion of immune tolerance in allotransplantation, as demonstrated by Jean-Paul Soulillou’s team, in collaboration with Efffimune in 2014 (reference). Read more >
License option agreement with Servier to develop and commercialize OSE-127 (Effi-7)
On December 28, 2016, OSE Immunotherapeutics has granted Servier, an independent international pharmaceutical company, a license option on the exclusive worldwide rights for the development and commercialization of its product OSE-127 (Effi-7). These steps will enable the development of the product up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease (Read the press release).
Attaining preclinical and clinical proofs of concept for OSE-127 (Effi-7) are the main goals of EFFIMab, a multidisciplinary program led by OSE Immunotherapeutics researchers along with several academic and private partners. This €20 million program is funded by the French public investment bank (Bpifrance) under the Industrial-Strategic-Innovation (ISI) program, which will finance a significant portion of the expenses incurred.